Fabrication, characterization and evaluation of anti-cancer and antibacterial properties of nanosystems containing Hedera Helix aqueous extracts

Document Type : Research Paper


1 Department of clinical biochemistry, Faculty of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran

2 Department of Medical Biotechnology, Faculty of Medicine, Shahid Sadoughi University of Medical sciences, Yazd, Iran

3 Department of biochemistry, Yazd Payame Noor University, Yazd, Iran

4 Medical Nanotechnology & Tissue Engineering Research Center, Yazd Reproductive Sciences Institute, Shahid Sadoughi University of Medical Sciences, Yazd, Iran

5 Department of Advanced Sciences and Technologies in Medicine, School of Medicine, North Khorasan University of Medical Sciences, Bojnurd, Iran

6 School of Medicine, North Khorasan University of Medical Sciences, Bojnūrd, Iran

7 Department of Psychology, University of New Mexico, Albuquerque, New Mexico, USA


In this study we synthesized and characterized nanoniosome containing Hedera Helix extract to evaluate its therapeutic properties on breast cancer cells in order to provide a new effective treatment strategy with low side effects for the treatment of this malignancy in the clinical stage. After extracting the Hedera helix by Soxhlet method, different formulations of noisomes containing the extract were synthesized and after investigating the load and release rate of the drug by spectrophotometry, the optimal formulation was selected. Then other physiochemical properties of nanosystems such as size and zeta potential by DLS method, system interaction and extract by FTIR method, system response to temperature and pH stimuli by spectrophotometry, nanoparticle morphology using SEM and AFM microscope, the stability of nanoparticles over 6 months and the antimicrobial properties of the system compared to the free form of extract were examined. Finally, the cellular uptake of nanosystem by flow cytometry microscope and its toxicity on MCF-7 and BT-474 breast cancer cell lines, MCF-10A breast normal cell line and HFF cell line were evaluated by MTT method. Results showed that the synthesized nanosystems with a size of 75.1 nm and PDI of 0.345 with a zeta potential of -20.6 ± 0.44 mV were morphologically suitable and had no interaction between niosomes and extracts. Also, the Encapsulation Efficiency in the system was 80.1 ± 2.2% and the drug release rate from the nanosystem was 57.2% in 72 hours. The stability of the system during 6 months and the response of the system to various stimuli was also appropriate. Also, encapsulation of the extract not only improved its antimicrobial properties compared to the extract, but also increased its anti-cancer effect on cancer cells although the nanosystem had no toxic effect on normal cells.


1.    DeSantis CE, Ma J, Gaudet MM, Newman LA, Miller KD, Goding Sauer A, et al. Breast cancer statistics, 2019. CA: a CA Cancer J Clin. 2019; 69(6): 438-451.
2.    Sun Y-S, Zhao Z, Yang Z-N, Xu F, Lu H-J, Zhu Z-Y, et al. Risk factors and preventions of breast cancer. Int J Biol Sci. 2017; 13(11): 1387.
3.    Tao Z, Shi A, Lu C, Song T, Zhang Z, Zhao J. Breast cancer: epidemiology and etiology. Cell Biochem Biophys. 2015; 72(2): 333-338.
4.    Núñez C, Capelo JL, Igrejas G, Alfonso A, Botana LM, Lodeiro C. An overview of the effective combination therapies for the treatment of breast cancer. Biomaterials. 2016; 97: 34-50.
5.    Nedeljković M, Damjanović A. Mechanisms of chemotherapy resistance in triple-negative breast cancer—how we can rise to the challenge. Cells. 2019; 8(9): 957.
6.    Sledge GW, Mamounas EP, Hortobagyi GN, Burstein HJ, Goodwin PJ, Wolff AC. Past, present, and future challenges in breast cancer treatment. J Clin Oncol. 2014; 32(19): 1979.
7.    Nikalje AP. Nanotechnology and its applications in medicine. Med Chem. 2015; 5(2): 081-089.
8.    Omidi M, Malakoutian M, Choolaei M, Oroojalian F, Haghiralsadat F, Yazdian F. A Label-Free detection of biomolecules using micromechanical biosensors. Chinese Phys Lett. 2013; 30(6): 068701.
9.    Oroojalian F, Beygi M, Baradaran B, Mokhtarzadeh A, Shahbazi MA. Immune Cell Membrane‐Coated Biomimetic Nanoparticles for Targeted Cancer Therapy. Small. 2021; 17(12): 2006484.
10.    Khatibi SA, Misaghi A, Moosavy MH, Basti AA, Koohi MK, Khosravi P, et al. Encapsulation of Zataria multiflora Bioss. essential oil into nanoliposomes and in vitro antibacterial activity against Escherichia coli O157: H7. J Food Process Preserv. 2017; 41(3): e12955.
11.    Koul B. Herbs for cancer treatment: Springer Nature; 2020.
12.    Akhlaghi M, Ebrahimpour M, Ansari K, Parnian F, Zarezadeh Mehrizi M, Taebpour M. Synthesis, study and characterization of nano niosomal system containing Glycrrizha glabra extract in order to improve its therapeutic effects. New Cellu Mol Biotech J. 2021; 11(42): 65-82.
13.    Al-Snafi AE. Pharmacological and therapeutic activities of Hedera helix-A review. IOSR J Pharm. 2018; 8: 41-53.
14.    Bezruk I, Marksa M, Georgiyants V, Ivanauskas L, Raudone L. Phytogeographical profiling of ivy leaf (Hedera helix L.). Ind Crops Prod. 2020; 154: 112713.
15.    Rahimizadeh M, Eshghi H, Shiri A, Ghadamyari Z, Matin MM, Oroojalian F, et al. Fe (HSO 4) 3 as an efficient catalyst for diazotization and diazo coupling reactions. J Korean Chem Soc. 2012; 56(6): 716-719.
16.    Abdelbary G, El-Gendy N. Niosome-encapsulated gentamicin for ophthalmic controlled delivery. AAPS pharmscitech. 2008; 9(3): 740-747.
17.    Kazi KM, Mandal AS, Biswas N, Guha A, Chatterjee S, Behera M, et al. Niosome: a future of targeted drug delivery systems. J Adv Pharm Technol. 2010;1(4):374.
18.    Mirhosseini M, Shekari-Far A, Hakimian F, Haghiralsadat BF, Fatemi SK, Dashtestani F. Core-shell Au@ Co-Fe hybrid nanoparticles as peroxidase mimetic nanozyme for antibacterial application. Process Biochem. 2020;95:131-8.
19.    Betzer O, Shilo M, Opochinsky R, Barnoy E, Motiei M, Okun E, et al. The effect of nanoparticle size on the ability to cross the blood–brain barrier: An in vivo study. Nanomed. 2017;12(13):1533-46.
20.    Gumushan‑Aktas H, Altun S. Effects of Hedera helix L. extracts on rat prostate cancer cell proliferation and motility. Oncol lett. 2016;12(4):2985-91.
21.    Barthomeuf C, Debiton E, Mshvildadze V, Kemertelidze E, Balansard G. In vitro activity of hederacolchisid A1 compared with other saponins from Hedera colchica against proliferation of human carcinoma and melanoma cells. Planta medica. 2002;68(08):672-5.
22.    Mokhtar M, Sammour OA, Hammad MA, Megrab NA. Effect of some formulation parameters on flurbiprofen encapsulation and release rates of niosomes prepared from proniosomes. Int J Pharm. 2008; 361(1-2): 104-111.
23.    Junyaprasert VB, Singhsa P, Suksiriworapong J, Chantasart D. Physicochemical properties and skin permeation of Span 60/Tween 60 niosomes of ellagic acid. Int J Pharm. 2012; 423(2): 303-11.
24.    Ruckmani K, Sankar V. Formulation and optimization of zidovudine niosomes. Aaps Pharmscitech. 2010; 11(3): 1119-1127.
25.    Pawlikowska-Pawlęga B, Dziubińska H, Król E, Trębacz K, Jarosz-Wilkołazka A, Paduch R, et al. Characteristics of quercetin interactions with liposomal and vacuolar membranes. Biochimica et Biophysica Acta (BBA)-Biomembranes. 2014; 1838(1): 254-265.
26.    Li Y-P, Pei Y-Y, Zhang X-Y, Gu Z-H, Zhou Z-H, Yuan W-F, et al. PEGylated PLGA nanoparticles as protein carriers: synthesis, preparation and biodistribution in rats. J Control Release. 2001; 71(2): 203-211.
27.    Hao Y-M. Entrapment and release difference resulting from hydrogen bonding interactions in niosome. Int J Pharm. 2011; 403(1-2) :245-253.
28.    Hemati M, Haghiralsadat F, Yazdian F, Jafari F, Moradi A, Malekpour-Dehkordi Z. Development and characterization of a novel cationic PEGylated niosome-encapsulated forms of doxorubicin, quercetin and siRNA for the treatment of cancer by using combination therapy. Artif Cells Nanomed Biotechnol. 2019; 47(1): 1295-1311.
29.    Choi SW, Zhang Y, Xia Y. A temperature‐sensitive drug release system based on phase‐change materials. Angewandte Chemie International Edition. 2010; 49(43): 7904-7908.
30.    Wu W, Zhang Q, Wang J, Chen M, Li S, Lin Z, et al. Tumor-targeted aggregation of pH-sensitive nanocarriers for enhanced retention and rapid intracellular drug release. Polym Chem. 2014; 5(19): 5668-5679.
31.    Alemi A, Reza JZ, Haghiralsadat F, Jaliani HZ, Karamallah MH, Hosseini SA, et al. Paclitaxel and curcumin coadministration in novel cationic PEGylated niosomal formulations exhibit enhanced synergistic antitumor efficacy. J Nanobiotechnology. 2018; 16(1): 1-20.
32.    Nowroozi F, Almasi A, Javidi J, Haeri A, Dadashzadeh S. Effect of surfactant type, cholesterol content and various downsizing methods on the particle size of niosomes. Iran J Pharm Sci. 2018; 17(Suppl2): 1.
33.    Agarwal S, Bakshi V, Vitta P, Raghuram A, Pandey S, Udupa N. Effect of cholesterol content and surfactant HLB on vesicle properties of niosomes. Indian J Pharm Sci. 2004; 66(1): 121-123.
34.    Marianecci C, Di Marzio L, Rinaldi F, Celia C, Paolino D, Alhaique F, et al. Niosomes from 80s to present: the state of the art. Adv. Colloid Interface Sci. 2014; 205: 187-206.
35.    Honary S, Zahir F. Effect of zeta potential on the properties of nano-drug delivery systems-a review (Part 2). Trop J Pharm Res. 2013; 12(2): 265-273.
36.    Zhang Y, Yang M, Portney NG, Cui D, Budak G, Ozbay E, et al. Zeta potential: a surface electrical characteristic to probe the interaction of nanoparticles with normal and cancer human breast epithelial cells. Biomed. Microdevices J. 2008; 10(2): 321-328.
37.    Naderinezhad S, Amoabediny G, Haghiralsadat F. Co-delivery of hydrophilic and hydrophobic anticancer drugs using biocompatible pH-sensitive lipid-based nano-carriers for multidrug-resistant cancers. RSC Advances. 2017; 7(48): 30008-30019.